Drug intelligence / Profile preview

Carya laciniosa pollen

Development stage: Unknown
Administration: Intradermal, Subcutaneous, Sublingual

Overview

Carya laciniosa pollen is an allergenic extract derived from the shellbark hickory tree, primarily utilized for the diagnosis and treatment of hickory pollen allergies. As a biologic product, it serves as a diagnostic tool in percutaneous or intradermal skin testing to identify hypersensitivity. Furthermore, it is employed in subcutaneous immunotherapy (allergy shots) to induce immunological tolerance in sensitized individuals. The extract contains the naturally occurring proteins and allergens found in the pollen of the Carya laciniosa species and is frequently used either as a standalone agent or as a component of standardized hickory pollen mixtures.

Other names: shellbark hickory pollenCarya laciniosa pollen extract

Targets

A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)

Beyond the preview

Go deeper on Carya laciniosa pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carya laciniosa pollen.

Explore the full profile